AFFILIATIONS
1 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
2 Lecheng Hospital of Sichuan University, Hainan, Asia, China, Mianyang Central Hospital School, Mianyang, Asia, China, West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
3 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
4 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
5 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
6 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
7 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
8 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
9 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
10 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, Asia, China
11 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
12 West China Hospital, Chengdu, Asia, China, West China Hospital, Chengdu, China, West China Hospital, Chengdu, China
ABSTRACT
Background: Adults with relapsed or refractory (r/r)EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) face dismal outcomes. While our previous pilot study demonstrated the efficacy of PD-1 inhibition in achieving disease control, robust biomarkers for long-term prognosis and durable response have yet to be established.
Methods: We retrospectively analyzed 85 adults with r/r EBV-HLH treated with PD-1 inhibitor–based therapy. Plasma EBV-DNA was serially measured. Associations of baseline viral load and plasma EBV-DNA status at 6 and 12 months with overall survival (OS) were evaluated using Cox regression and landmark analyses. Post-landmark OS was calculated from the corresponding landmark.
Results: Median OS was 27.03 months. Baseline plasma EBV-DNA level showed no association with OS. By contrast, detectable EBV-DNA at 6 and 12 months was significantly associated with inferior post-landmark OS. In the 6-month landmark cohort, multivariable analysis identified EBV-DNA positivity as an independent predictor of worse OS (HR, 8.113; P = 0.001), alongside serum creatinine. At the 12-month landmark, EBV-DNA positivity emerged as the sole independent prognostic factor (HR, 8.184; P = 0.009). Notably, sustained EBV-DNA negativity was associated with favorable long-term survival, whereas persistent positivity identified a high-risk subgroup even under PD-1 inhibitor–based therapy.
Conclusions: Serial plasma EBV-DNA monitoring outperforms baseline viral load as a prognostic tool in adults with r/ r EBV-HLH receiving PD-1 blockade. EBV-DNA status at 6 months and 1 year represents actionable decision points, identifying patients who require treatment intensification or transition versus those likely to achieve durable control. These findings support integrating on-treatment viral kinetics into risk-adapted management strategies. Prospective validation is warranted to establish dynamic EBV-DNA as a standard-of-care biomarker in this setting.